Blood Acceptance Rate

Blood's 19.4 impact factor puts it alongside Nature Immunology and Immunity in citation metrics. But its acceptance rate (~15-20%) is notably higher than those journals (~8-10%). The reason: Blood publishes in a single specialty (hematology) with enormous breadth within that specialty.

The journal accepts:

• Basic hematology (stem cells, coagulation, hemoglobin biology)
• Clinical hematology (treatment outcomes, clinical trials)
• Translational hematology (bench-to-bedside in blood diseases)
• Blood banking and transfusion medicine
• Immunohematology

This breadth means more paper types find a home. A clinical trial in lymphoma, a basic study on platelet signaling, and a transfusion safety paper can all be published in the same issue. That diversifies the submission pool and raises the acceptance rate relative to narrower journals.

The desk: scope and rigor

Blood's desk rejection rate (~40-50%) is lower than Nature or Cell (~70-80%). The editors are less concerned with "is this exciting enough?" and more concerned with "is this real hematology with adequate rigor?"

Common desk rejection reasons:

• The paper is tangentially related to blood but isn't really hematology (oncology papers about solid tumors, immunology papers without a blood connection)
• The methodology has obvious flaws that won't survive review
• The clinical study is too small or the endpoints are too weak for the claim
• The paper duplicates recently published findings without adding a new dimension

Peer review: field-specific rigor

Blood reviewers are practicing hematologists and hematology researchers. They know the field deeply. Papers get rejected after review when:

• The hematology community already knows this (incremental finding)
• The model system doesn't translate well to human blood disease
• The clinical data has selection bias or endpoint problems that weren't apparent at triage
• The paper is technically correct but doesn't advance the field

Submit if:

• the finding advances hematology in a way the community will build on
• the paper is clearly hematology (blood cells, blood diseases, transfusion, coagulation)
• the methodology is rigorous enough for specialty-level scrutiny
• the clinical or translational relevance is clear for a hematology audience

Think twice if:

• the hematology connection is secondary (the paper is really oncology, immunology, or biochemistry)
• Blood Advances would be a faster path to the same audience
• JCO or Leukemia is a more natural fit for the specific topic
• the finding is incremental for the hematology community

A free manuscript scan can help assess whether the hematology framing and evidence strength meet Blood's editorial expectations.

What is the Blood journal acceptance rate?

Approximately 15-20%. More accessible than Nature or Cell but still selective.

Is Blood easier to get into than its impact factor suggests?

Somewhat. The 19.4 IF is comparable to Nature Immunology, but Blood's acceptance rate (~15-20%) is nearly double. The journal's broad scope within hematology creates more slots for different paper types.

What's the difference between Blood and Blood Advances?

Blood (IF 19.4) is the flagship. Blood Advances (IF ~7) accepts solid hematology below the flagship threshold. Both are ASH journals with the same reviewer community.

Does Blood favor clinical or basic papers?

Both. The journal publishes the full spectrum from molecular hematology to clinical trials. The balance shifts by issue, but neither type is disadvantaged.